Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria.
about
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's diseasePathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and RehabilitationMolecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision MedicineIndividual differences in approach-avoidance aptitude: some clues from research on Parkinson's diseaseAlpha-synuclein biology in Lewy body diseasesSystems biology of neurodegenerative diseasesFBXO7 immunoreactivity in α-synuclein-containing inclusions in Parkinson disease and multiple system atrophyTranslation initiator EIF4G1 mutations in familial Parkinson diseaseLipid pathway alterations in Parkinson's disease primary visual cortexMicrostructural changes in the substantia nigra of asymptomatic agricultural workersAuditory- and Vestibular-Evoked Potentials Correlate with Motor and Non-Motor Features of Parkinson's Disease.First neuropathological description of a patient with Parkinson's disease and LRRK2 p.N1437H mutationGBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology.The curious case of phenocopies in families with genetic Parkinson's disease.Clinicopathological outcomes of prospectively followed normal elderly brain bank volunteers.ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodiesThe neurobiological basis of cognitive impairment in Parkinson's disease.CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's diseaseDNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E in vitroEmbryonic development of selectively vulnerable neurons in Parkinson's disease.Subregional 6-[18F]fluoro-ʟ-m-tyrosine uptake in the striatum in Parkinson's disease.Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.A pivotal role for PINK1 and autophagy in mitochondrial quality control: implications for Parkinson disease.Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body DisordersPathologic correlates of dementia in individuals with Lewy body disease.Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic studyWhy psychosis is frequently associated with Parkinson's disease?Huntington's disease (HD): degeneration of select nuclei, widespread occurrence of neuronal nuclear and axonal inclusions in the brainstem.Diagnosis and treatment of common forms of tremor.The management of gastrointestinal symptoms in Parkinson's disease.Incidence of dementia with Lewy bodies and Parkinson disease dementiaMitochondrial abnormality associates with type-specific neuronal loss and cell morphology changes in the pedunculopontine nucleus in Parkinson diseaseDisentangling the relationship between lewy bodies and nigral neuronal loss in Parkinson's disease.When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patientsRTCB-1 mediates neuroprotection via XBP-1 mRNA splicing in the unfolded protein response pathway.Longitudinal changes in cognition in Parkinson's disease with and without dementia.Unbiased approaches to biomarker discovery in neurodegenerative diseasesAbnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimer's disease using the Multiple Sleep Latency Test.Altered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease.Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies.
P2860
Q24324577-EE32CC95-DC2A-48FE-AD27-65E081999C37Q26745654-15CE544F-199F-4701-A31E-ED8E6F303CC1Q26768648-EA6F6EA0-941F-4824-BF46-51820A2B5198Q26860706-BE74D431-DCE2-4832-BBC2-6310029FBDD4Q27003541-22B6F843-976D-4C63-A84B-0EDEEC86B40EQ28080741-6F311AD3-B43D-43D1-B45C-1B451962911FQ28117902-53153DFC-5D26-4AD6-9537-AA1B1212C7A5Q28247679-2CDB62B0-D887-46C3-B700-FB5ED4236F49Q28386548-CFDE4EFE-BBF3-485B-BD10-01FEE2BB9C12Q28397004-AADF417D-D35A-4D7C-932A-DBCCFED25457Q30361239-CDBC2101-C847-4D27-AFF8-E80C12397504Q30513503-BEC4A6F7-585C-401D-9B7B-838C7545E4C6Q30527838-2A2DB826-0EF7-4596-B98E-AFF2EECE54A6Q33351731-94E58628-F80B-4C7B-A8C5-F6036505062FQ33456273-0925D8F1-6542-4D39-8F03-24BFE72970A4Q33715666-3701AD3C-CE35-483A-8257-8525DE52ABA7Q33724698-5454A144-6E44-476D-8323-FD54A2F4C9B4Q33760744-0F1E8A24-A6C8-496F-AAA5-F26E4430536DQ33818001-61E63255-7884-462C-9B38-23296D15FC48Q33835242-4D134EC1-AF2A-43A4-AEEB-58C1D01708CBQ33853332-09637725-B9F1-4953-95B8-78DB3D759E11Q33869820-28BC6630-8FF8-414F-80B1-5886E252B57EQ33871331-28401782-7D8A-48BD-BB32-EC29623A821CQ33874572-653EA332-6191-4AA4-B2C4-02C29CBE3801Q33896668-2DB3A35E-2933-4925-B0F4-016D4A08D1EFQ34043770-369EA271-47E8-4FBE-A801-94500324B2E1Q34094668-2877367E-B116-494C-9EE1-AB8CD6A4D412Q34162629-EA13D751-C28A-4ACD-ABA1-6AD3BEF21493Q34164665-F19104C2-248D-43C9-9E59-CA94C73F6DCAQ34250597-9F9D5F1D-CABB-4B46-97B6-AF14ED8F7A66Q34275050-1E71EBBE-F304-47DA-8E14-DB63CD518D1BQ34299923-D7734D91-1A2A-4A92-8D5B-E58B6A7537F0Q34336792-3BB5125E-5E16-4F59-A3EC-61DFABCBF70FQ34483397-BA53E662-B86B-4193-9EF0-F8BD1EEA7BCEQ34573419-A752BE02-C1EA-4D6E-85DF-F15D6440C92BQ34619632-5A34E2E8-80C7-4C36-9EC6-8699CB9EA544Q34625918-2AF6723C-D375-4357-B985-6BF2E826122DQ34703509-E8A518BB-FF1C-471C-8081-1D4D940ADD65Q34760606-9B1048AF-A341-4283-B58F-EEE7B790551FQ35006687-FD64BF7E-2BD4-4F26-A4BE-59A09C875A72
P2860
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria.
@en
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria.
@nl
type
label
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria.
@en
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria.
@nl
prefLabel
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria.
@en
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria.
@nl
P2093
P50
P1433
P1476
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria.
@en
P2093
Charles Duyckaerts
Heiko Braak
John E Duda
Kelly Del Tredici
P304
P356
10.1016/S1474-4422(09)70238-8
P50
P577
2009-12-01T00:00:00Z